<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974258</url>
  </required_header>
  <id_info>
    <org_study_id>GO29026</org_study_id>
    <nct_id>NCT01974258</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients</brief_title>
  <official_title>A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the maximum tolerated dose and dose-limiting toxicities of
      vemurafenib and/or cobimetinib when used with onartuzumab in cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of dose-limiting toxicities (DLTs) of vermurafenib and/or cobimetinib used in combination with onartuzumab.</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of anti-therapeutic antibodies against onartuzumab.</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events (AE)</measure>
    <time_frame>24 to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of onartuzumab</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of cobimetinib</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (Cmax) of vemurafenib</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall response rate</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Progression-free survival</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Duration of response</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall survival</measure>
    <time_frame>24 to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Escalating dose</description>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Orally administered once daily for 21 consecutive days, followed by 7 days off.</description>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onartuzumab</intervention_name>
    <description>Administered by IV infusion every 2 weeks</description>
    <arm_group_label>Dose-expansion: onartuzumab + cobimetinib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Orally administered twice daily</description>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib</arm_group_label>
    <arm_group_label>Dose-expansion: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
    <arm_group_label>Dose-finding: onartuzumab + vemurafenib + cobimetinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;/= 18 years of age.

          -  Patients with histologically confirmed, BRAFV600-mutant, unresectable, locally
             advanced or metastatic solid malignancies. OR

          -  Patients with a histologically confirmed, KRAS-mutant, Stage IV colorectal
             adenocarcinoma, or KRAS-mutant metastatic non-small-cell lung carcinoma. OR

          -  Patients with histologically confirmed BRAFV600-mutant unresectable Stage IIIC or
             Stage IV metastatic melanoma.

          -  Valid MET IHC test result.

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors v1.1

          -  ECOG performance status of 0 or 1.

          -  For BRAFV600-mutant cancers:

          -  Previously untreated for their melanoma or previously treated for their melanoma but
             without prior exposure to any HGF, MET, BRAF, or MEK inhibitor therapy

          -  BRAFV600-mutant solid malignancies other than melanoma for which standard therapy does
             not exist has proven to be ineffective or intolerable or is considered inappropriate.

        Patients must not have had prior exposure to HGF, MET, BRAF, or MEK inhibitor therapy.

          -  For KRAS-mutant cancers:

          -  mCRC patients must have received therapeutic regimens including oxaliplatin,
             irinotecan, 5-FU, and bevacizumab, or determined to be ineligible for these
             treatments. Patients must not have had prior exposure to HGF, MET, BRAF, or MEK
             inhibitor therapy.

          -  Metastatic NSCLC patients must have received platinum-based doublet chemotherapy or
             determined to be ineligible for this regimen. Patients must not have had prior
             exposure to HGF, MET, BRAF, or MEK inhibitor therapy.

          -  Consent to provide tumor tissue for biomarker analyses.

          -  Life expectancy &gt;/= 12 weeks.

          -  Fully recovery from the effects of any major surgery or significant traumatic injury
             within 14 days from the first dose of study treatment.

          -  Adequate hematologic and end organ function, as defined by clinical laboratory
             results.

          -  Use of effective form(s) of contraception as defined by protocol during the course of
             this study and for at least 6 months after study drug discontinuation.

        Exclusion Criteria:

          -  Palliative radiotherapy or experimental therapy within 28 days prior to first dose of
             study drug treatment.

          -  Major surgical procedure or significant traumatic injury from 28 days prior to first
             dose of study drug treatment until end of study.

          -  History of another malignancy in the previous 5 years, unless cured by surgery alone
             and continuously disease free. Exceptions include appropriately treated cervical
             carcinoma in situ, non-melanoma skin carcinoma, Stage I uterine cancer, localized
             prostate cancer that has been treated surgically and is presumed cured, or other
             malignancies with an expected curative outcome.

          -  Brain metastasis or spinal cord compression not definitively treated with surgery
             and/or radiation, or previously diagnosed and treated central nervous system (CNS)
             metastases or spinal cord compression without evidence of clinically stable disease
             for more than 14 days.

        Note: Patients with treated CNS metastases who are asymptomatic and on a stable dose of
        corticosteroids for more than 14 days prior to Cycle 1 Day 1 are eligible.

          -  For patients given cobimetinib: Evidence of visible retinal pathology that is
             considered a risk factor for neurosensory detachment, retinal vein occlusion, or
             neovascular macular degeneration, or of conditions that are risk factors for retinal
             vein occlusion.

          -  Current or history of clinically significant cardiac or pulmonary dysfunction.

          -  Lack of recovery to Grade 1 or better from adverse events due to investigational or
             other agents administered more than 28 days prior to enrollment, except for alopecia.

          -  Current severe, uncontrolled systemic disease.

          -  Inability or unwillingness to swallow pills.

          -  History of malabsorption or other condition that would interfere with gastrointestinal
             absorption of study drug.

          -  History of clinically significant liver disease, current alcohol abuse, or known
             infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).

          -  Severe (Grade 3 and above) active infection at enrollment, or other serious underlying
             medical conditions.

          -  Required medication known to cause edema and/or cardiac failure.

          -  Active autoimmune disease.

          -  Uncontrolled ascites requiring weekly, large-volume paracentesis for 3 consecutive
             weeks prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

